The Secukinumab in Behcet’s trial
The Secukinumab in Behcet’s trial aim
This study is looking at a potential new treatment, Secukinumab for patients diagnosed with non-ocular Behcet’s Syndrome. This is a randomised placebo controlled trial of either the drug (secukinumab) or placebo and wants to evaluate how safe and how effective Secukinumab might be for participants with Behcet’s disease.
Taking part
If you have been diagnosed with Behcet’s and have previously not responded to first line therapy with topical steroid (mouth wash or skin cream), colchicine or azathioprine, you could be eligible to take part in the trial.
Why is it important?
Taking part could help to make a difference to your quality of life, and in the process assist others in the future.
What should I do next?
If you would like more information about this study, please contact a member of your usual Behcet’s care team, or the contacts below. They will be able to discuss the study further with you, answer any questions you might have and let you know whether you are eligible to take part.
Trial team at The Royal London Hospital
Address:
Behcet’s Syndrome Centre of Excellence (London),
Dental Hospital
The Royal London Hospital
Turner Street,
Whitechapel,
London
E1 1BB
Tel: 020 3416 5000; Ext: 46089
Email:
Take part in research at Barts Health